Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
| Last: | $2.36 |
|---|---|
| Change Percent: | 0.0% |
| Open: | $2.71 |
| Close: | $2.36 |
| High: | $2.91 |
| Low: | $2.25 |
| Volume: | 310,975 |
| Last Trade Date Time: | 06/18/2025 03:54:05 pm |
| Market Cap: | $1,122,494 |
|---|---|
| Float: | 4,574,629 |
| Insiders Ownership: | N/A |
| Institutions: | 6 |
| Short Percent: | 66935% |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | www.lipella.com |
| Country: | US |
| City: | Pittsburgh |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Lipella Pharmaceuticals Inc. (NASDAQ: LIPO).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
